Literature DB >> 20845286

Induction of breast cancer in wild type p53 cells by BRCA1-IRIS overexpression.

Wael M Elshamy1.   

Abstract

Cells ability to evade cell death and to proliferate post geno-/cell-toxic stresses, likely leads to formation of cancer. Activation of p38MAPK and p53 following these stresses help protect cells against cancer development by initiating apoptosis. The duration of p38MAPK and p53 activation is regulated by the WIP1 phosphatase. BRCA1-IRIS triggers WIP1 expression in p53-dependent and -independent manner. BRCA1-IRIS triggers the expression and cytoplasmic localization of the mRNA stabilization and translation inducer, HuR that binds p53 and PPM1D mRNA. Hence, BRCA1-IRIS overexpression inactivates p38MAPK and/or p53 by upregulating WIP1 expression. BRCA1-IRIS abrogation of the homeostatic balance maintained by p38MAPK-p53-WIP1 pathway suppressed cell death induced by a lethal dose of UVC, high dosages of etoposide or H2O2, and allowed cells to survive and proliferate post geno-/cell-toxic stresses. This mechanism represents a new link between geno-/cell-toxic stress and aggressive breast cancer formation in p53 wild-type cells. Hawaii Medical Journal Copyright 2010.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20845286      PMCID: PMC3118025     

Source DB:  PubMed          Journal:  Hawaii Med J        ISSN: 0017-8594


  12 in total

Review 1.  Cellular UV damage responses--functions of tumor suppressor p53.

Authors:  Leena Latonen; Marikki Laiho
Journal:  Biochim Biophys Acta       Date:  2005-07-25

Review 2.  MAP kinase: it's been longer than fifteen minutes.

Authors:  Thomas W Sturgill
Journal:  Biochem Biophys Res Commun       Date:  2008-04-10       Impact factor: 3.575

3.  BRCA1-IRIS activates cyclin D1 expression in breast cancer cells by downregulating the JNK phosphatase DUSP3/VHR.

Authors:  Lu Hao; Wael M ElShamy
Journal:  Int J Cancer       Date:  2007-07-01       Impact factor: 7.396

4.  Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner.

Authors:  M Fiscella; H Zhang; S Fan; K Sakaguchi; S Shen; W E Mercer; G F Vande Woude; P M O'Connor; E Appella
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

5.  Substrate specificity of the human protein phosphatase 2Cdelta, Wip1.

Authors:  Hiroshi Yamaguchi; Giuseppina Minopoli; Oleg N Demidov; Deb K Chatterjee; Carl W Anderson; Stewart R Durell; Ettore Appella
Journal:  Biochemistry       Date:  2005-04-12       Impact factor: 3.162

6.  BRCA1-IRIS regulates cyclin D1 expression in breast cancer cells.

Authors:  Enkeleda Nakuci; Sven Mahner; James Direnzo; Wael M ElShamy
Journal:  Exp Cell Res       Date:  2006-06-21       Impact factor: 3.905

7.  Apigenin prevents UVB-induced cyclooxygenase 2 expression: coupled mRNA stabilization and translational inhibition.

Authors:  Xin Tong; Rukiyah T Van Dross; Adnan Abu-Yousif; Aubrey R Morrison; Jill C Pelling
Journal:  Mol Cell Biol       Date:  2006-10-30       Impact factor: 4.272

8.  Identification of BRCA1-IRIS, a BRCA1 locus product.

Authors:  Wael M ElShamy; David M Livingston
Journal:  Nat Cell Biol       Date:  2004-09-26       Impact factor: 28.824

9.  Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway.

Authors:  Dmitry V Bulavin; Crissy Phillips; Bonnie Nannenga; Oleg Timofeev; Larry A Donehower; Carl W Anderson; Ettore Appella; Albert J Fornace
Journal:  Nat Genet       Date:  2004-02-29       Impact factor: 38.330

10.  Expression of vascular endothelial growth factor-A and mRNA stability factor HuR in human meningiomas.

Authors:  Takahiro Sakuma; Takao Nakagawa; Kazunori Ido; Hiroaki Takeuchi; Kazufumi Sato; Toshihiko Kubota
Journal:  J Neurooncol       Date:  2008-06       Impact factor: 4.130

View more
  1 in total

Review 1.  BRCA1-No Matter How You Splice It.

Authors:  Dan Li; Lisa M Harlan-Williams; Easwari Kumaraswamy; Roy A Jensen
Journal:  Cancer Res       Date:  2019-04-16       Impact factor: 12.701

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.